학술논문
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
Document Type
Article
Author
Toledo-Romaní, María Eugenia; García-Carmenate, Mayra; Valenzuela-Silva, Carmen; Baldoquín-Rodríguez, Waldemar; Martínez-Pérez, Marisel; Rodríguez-González, Meiby; Paredes-Moreno, Beatriz; Mendoza-Hernández, Ivis; González-Mujica Romero, Raúl; Samón-Tabio, Oscar; Velazco-Villares, Pablo; Bacallao-Castillo, Juan Pablo; Licea-Martín, Ernesto; Rodríguez-Ortega, Misladys; Herrera-Marrero, Nuris; Caballero-González, Esperanza; Egües-Torres, Liudmila; Duartes-González, Reinaldo; García-Blanco, Serguey; Pérez-Cabrera, Suzette; Huete-Ferreira, Santos; Idalmis-Cisnero, Kirenia; Fonte-Galindo, Omayda; Meliá-Pérez, Dania; Rojas-Remedios, Ivonne; Doroud, Delaram; Gouya, Mohammad Mehdi; Biglari, Alireza; Fernández-Castillo, Sonsire; Climent-Ruiz, Yanet; Valdes-Balbín, Yury; García-Rivera, Dagmar; Van der Stuyft, Patrick; Verez-Bencomo, Vicente
Source
In The Lancet Regional Health - Americas February 2023 18
Subject
Language
ISSN
2667-193X